Europe
The two generic drugmakers, along with many others, have been accused of conspiring to inflate the price of more than 100 generic drugs.
Treatment Disparities Prevent Indicated Patients from Receiving
Medtronic plc announced today that it will report financial results for its fourth quarter and fiscal year 2019 on Thursday, May 23, 2019.
GENFIT today announced that it published in May 8, 2019’s French legal announcements bulletin (Bulletin des Annonces Légales Obligatoires) its convening notice to the Ordinary Shareholders’ Meeting to be held on Thursday, June 13, 2019, at 2:30pm, at the Faculty of Pharmaceutical & Biological Sciences of Lille, located Parc Eurasanté, 3 rue du Professeur Laguesse, 59000 Lille, France.
Acquisition Further Accelerates Medtronic’s Strategy to Transform Spinal Procedures and Improve Outcomes Through Complete Procedural Solutions
Peter Rowe, Deep Branch Biotechnology’s co-founder and Commercial Lead, took time to speak with BioSpace about his company, its progress, and where it’s headed.
Almost every week, biopharma companies release results from ongoing clinical trials. Here’s a roundup of some of the top clinical trial news from the previous week.
The triple combination therapy does not use a chemotherapy agent in its experimental treatment for an aggressive blood cancer.
Polyphor announced the decision to temporarily halt enrollment for the pivotal Phase III trials PRISM-MDR and PRISM-UDR evaluating murepavadin in patients with nosocomial pneumonia due to higher than expected acute kidney injury incidences in the murepavadin arm of the PRISM-MDR trial.
CENTOGENE announced the expansion of its executive leadership team with the appointment of Sun Kim in Boston, MA asChief Strategy & Investor Relations Officer.
PRESS RELEASES